Kymera Investor Presentation Deck

As of the data cut-off of June 1, 2023: ● PK and PD profiles in DL1-4* consistent with preclinical data supporting once every three-week dosing regimen ● Desired Translation of PK, PD and Safety of KT-413 ● ● KT-413 achieved dose-dependent degradation of up to 70% IRAK4 and 96-100% Ikaros and Aiolos in PBMC after a single dose Consistent degradation in blood and tumor Profile that in preclinical species led to robust antitumor activity in MYD88 mutant tumors The most common adverse events were fatigue, cough and pyrexia.** No DLTs or drug-related neutropenia were observed in the study. Expect to be at potentially clinically active profiles at DL3-4 and beyond. *DL1-3 have been completed and DL4 remains open to accrual. **AEs related to KT-413 were all Grade 1 and 2; SAEs (Gr. 4 sepsis and Gr. 4 lung infection) reported in one patient in DL3 occurred outside of the DLT window at the end of Cycle 2 in the setting of disease progression. KYMERA ©2023 KYMERA THERAPEUTICS, INC. Potential to be First Precision Medicine in DLBCL to Target a Genetically- defined Population (MYD88MT) Profound antitumor activity in preclinical models both in single agent and combination Clinical strategy in place to enable accelerated approval: Monotherapy MYD88MT DLBCL for most direct path to registration Other MYD88MT lymphomas of interest include PCNSL, WM Combinations With SOC agents in MYD88MT DLBCL to enable earlier line therapy PAGE 40

View entire presentation